SCHEDULE: Strategic EP Discloses 6.8% Stake in Alaunos Therapeutics

Strategic EP, LLC has reported a 6.8% beneficial ownership stake in Alaunos Therapeutics, Inc., alongside a standstill agreement that limits its influence.

Summary

• Strategic EP, LLC beneficially owns 149,827 shares of Alaunos Therapeutics, Inc. Common Stock.
• This represents 6.8% of the outstanding Common Stock, based on 2,205,716 shares as of August 20, 2025.
• The ownership percentage does not include 62,299 shares issuable upon exercise of pre-funded warrants due to existing ownership limitations.
• A Standstill Agreement was entered into on August 26, 2025, allowing Strategic EP, LLC to exceed the 4.99% ownership limit up to 9.99% as permitted under the terms of the pre-funded warrant agreement.
• Under the Standstill Agreement, Strategic EP, LLC waived any rights to engage in takeover-related activities or otherwise seek to influence or control Alaunos Therapeutics.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment in Alaunos Therapeutics, which is generally positive. The standstill agreement provides clarity on the investor's intent, avoiding potential activist scenarios, which can be viewed favorably by existing management and long-term shareholders. However, it does not provide new operational or financial performance data.

Positives

• A significant institutional investor, Strategic EP, LLC, has taken a substantial stake, potentially indicating confidence in the company's long-term prospects.
• The Standstill Agreement provides stability by preventing the investor from engaging in hostile takeover activities or seeking to control the Issuer, which can reduce uncertainty for current management and other shareholders.

Negatives

• The standstill agreement limits the ability of a significant shareholder to influence management or strategic direction, which could be a negative if the company's performance falters and shareholder intervention is needed.
• The pre-funded warrants have ownership limitations (4.99% or 9.99%), suggesting a cautious approach by the investor to avoid triggering certain regulatory or corporate governance thresholds.

Risks

• The existence of pre-funded warrants with ownership limitations (4.99% or 9.99%) could indicate potential dilution if fully exercised, although these shares are not currently included in the beneficial ownership calculation due to these limitations.
• The Standstill Agreement restricts Strategic EP, LLC's ability to influence or control the Issuer, which could be a risk if the company's performance requires active shareholder engagement.

Future Outlook

NA

Industry Context

This filing indicates an institutional investor's confidence in Alaunos Therapeutics, a biotechnology company. Such investments are common in the biotech sector, where companies often rely on external capital and long-term investors to fund research and development. The standstill agreement is a common mechanism to manage investor influence while securing investment.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to institutional investment, but potential limitation on future activist influence.
• Management: Enhanced stability and reduced risk of hostile takeover attempts due to the standstill agreement.

Key Dates

Recommendation

The filing indicates a significant institutional investment and a standstill agreement, which provides some stability. However, it does not contain new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The information is primarily about ownership structure and investor intent, suggesting a 'hold' until further fundamental updates are available.

Keywords

Alaunos Therapeutics, Strategic EP, Schedule 13G, Beneficial Ownership, Common Stock, Standstill Agreement, Pre-funded Warrants, Biotechnology Investment, Institutional Investor